<DOC>
	<DOCNO>NCT00002721</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness doxorubicin plus estramustine treating patient metastatic recurrent prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Doxorubicin Plus Estramustine Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate maximum tolerate dose weekly intravenous doxorubicin ( DOX ) give combination oral estramustine ( EM ) patient metastatic prostate cancer refractory treatment hormonal agent . II . Assess frequency expression multidrug resistance phenotype biopsy specimens patient . III . Assess response DOX/EM patient . OUTLINE : 2-Drug Combination Chemotherapy . Doxorubicin , DOX , NSC-123127 ; Estramustine , EM , NSC-89199 . PROJECTED ACCRUAL : Three 18 patient enter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy proven metastatic prostate cancer Biopsy requirement waive principal investigator 's discretion new disease site technically inaccessible PSA elevate Recurrent disease follow orchiectomy , estrogen , gonadotropinreleasing hormone agonist therapy If previously irradiate : Progressive disease outside prior radiotherapy field require No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 mg/dL ALT/AST le 3 time great normal Renal : Not specify Cardiovascular : Left ventricular ejection fraction least 45 % No NYHA class III/IV status No unstable angina Other : No Crohn 's disease , ulcerative colitis , inflammatory bowel syndrome PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior doxorubicin estramustine Endocrine therapy : See Disease Characteristics At least 30 day since flutamide Estrogen gonadotropinreleasing hormone agonist discontinue prior treatment Radiotherapy : At least 6 week since radiotherapy Surgery : Not specify</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>recurrent prostate cancer</keyword>
</DOC>